PREVENTING LIVER CANCER

Assessing the benefits and costs of risk-stratified surveillance for patients with metabolic-associated fatty liver disease


MAFLD and MASH

About one in three Australians have metabolic-associated fatty liver disease, or MAFLD - a liver disease common in people who are overweight, obese, or have other metabolic conditions.






MAFLD can develop to metabolic-associated steatohepatitis, or MASH, through liver inflammation MASH affects about **one in twenty** Australians and increases the likelihood of hepatocellular carcinoma (HCC), a common liver cancer



3% of people with MAFLD will develop HCC over their lifetime...

> ...but 17% of people with MASH will develop HCC over their lifetime

Targeted routine liver surveillance can reduce the likelihood of HCC death by 27% in MASH patients while improving cost-effectiveness to \$16,000 per life-year saved and reducing resource burden



https://preventioncentre.org.au/research-projects/preventing-liver-cancer

Sources:

- The D²ffodil Centre Adams LA et al. Nonalcoholic fatty liver disease burden: Australia, 2019-2030. J Gastroenterol Hepatol, 2020 Yeoh et al. Temporal Change in Etiology and Clinical Characteristics of Hepatocellular Carcinoma in a Large Cohort of Patients with Cancer Council SYDNEY
- Hepatocellular Carcinoma in New South Wales, Australia. Gastroenterology; 2023 Younossi ZM et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016.